Last $0.47 USD
Change Today +0.0009 / 0.19%
Volume 248.0K
ONCY On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONCY) Snapshot

Open
$0.52
Previous Close
$0.47
Day High
$0.53
Day Low
$0.45
52 Week High
10/23/13 - $2.89
52 Week Low
10/10/14 - $0.40
Market Cap
41.9M
Average Volume 10 Days
393.9K
EPS TTM
--
Shares Outstanding
89.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONCY)

oncolytics biotech inc (ONCY) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONCY) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONCY) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

oncolytics biotech inc (ONCY) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: C$530.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: C$280.0K
Chief Operating Officer and Director
Total Annual Compensation: C$365.0K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: C$331.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $271.2K
Compensation as of Fiscal Year 2013.

oncolytics biotech inc (ONCY) Key Developments

Oncolytics Biotech Inc. - Special Call

To discuss detailed data from the randomized Phase 2 study in pancreatic cancer (NCI-8601)

Oncolytics Biotech Inc. Announces Overall and KRAS-Mutated Patient Data from U.S. Randomized Phase 2 Pancreatic Cancer Study

Oncolytics Biotech Inc. announced overall and KRAS-mutated patient data from a two-arm randomized phase 2 study of carboplatin, paclitaxel plus REOLYSIN (test arm) versus carboplatin and paclitaxel alone (control arm) in the first line treatment of patients with recurrent or metastatic pancreatic cancer (NCI-8601). The trial is sponsored by the U.S. National Cancer Institute (NCI) through a clinical trials agreement between the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis and Oncolytics. Oncolytics provided clinical supplies of REOLYSIN for the study and paid for the immune and genetic testing of the patients. The overall objectives of the study were to determine the progression free survival of the overall patient population and the patient population according to KRAS mutation status. The study enrolled 73 patients, 37 were in the control arm, 36 were in the test arm. The median progression free survival for the control arm was 5.16 months (95% confidence interval (CI) = 2.267 to 6.176) versus 5.26 months for the test arm (95% CI = 3.187 to 6.307). KRAS mutated patient population: As part of the study design, patients were screened for KRAS status at codon 12. Of the 60 patients where KRAS status could be determined (mutant versus wild type), 44 (73%) had mutations in the KRAS gene (n = 23 in the control arm, n = 21 in the test arm). Median progression free survival in the test arm was 5.72 months (95% CI = 3.187 to 6.767) versus 4.11 months in the control arm (95% CI = 1.938 to 6.176). This translates into a 1.61 month (39%) improvement in median progression free survival in the test arm versus the control arm. Three patients on the test arm and one on the control arm had not progressed as of the time of analysis. Kaplan-Meier plot of the Progression Free Survival (PFS) of the control arm versus the test arm of the KRAS mutated patient population.

Oncolytics Biotech Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase 2 Ovarian Cancer Study

Oncolytics Biotech Inc. announced that patient enrollment has been completed in a randomized Phase 2 study of paclitaxel plus REOLYSIN(R) versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The current study is a randomized Phase 2 trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer. Patients were randomized to receive either paclitaxel alone or paclitaxel plus REOLYSIN. Patients in both arms received treatment with paclitaxel, with the second arm also receiving intravenous REOLYSIN. Patients received standard doses of paclitaxel on days one, eight, and 15 every 28 days. In the second arm, patients received, on days one through five of each 28-day cycle, intravenous REOLYSIN at a dose of 3x10(10) TCID(50). The primary objectives of the trial are to estimate the progression-free survival hazard ratio of the combination of weekly paclitaxel with REOLYSIN to weekly paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer and to determine the frequency and severity of adverse events associated with treatment with weekly paclitaxel alone and weekly paclitaxel with REOLYSIN as assessed by Common Terminology Criteria for Adverse Events (CTCAE). The secondary objectives are to estimate the progression-free survival and overall survival of patients treated with weekly paclitaxel alone and weekly paclitaxel with REOLYSIN; to estimate (and compare) the proportion of patients who respond to the regimen on each arm of the study (according to RECIST 1.1 with measurable patients and by CA-125 for those patients with detectible disease only); and to characterize and compare progression-free survival and overall survival in patients with measurable disease (RECIST 1.1 criteria) and patients with detectable (nonmeasurable) disease. The study enrolled approximately 150 patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCY:US $0.47 USD +0.0009

ONCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCY.
View Industry Companies
 

Industry Analysis

ONCY

Industry Average

Valuation ONCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.